Trial Profile
Controlled Trial on the Short-term Effects of Sacubitril/Valsartan Therapy on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Patients With NYHA II-III Heart Failure and Reduced Systolic Function Using 11C-acetate Positron Emission Tomography and Echocardiography
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms TurkuPET
- Sponsors Novartis Pharmaceuticals
- 29 Apr 2022 Status changed from recruiting to completed.
- 31 Mar 2021 Planned End Date changed from 28 Feb 2021 to 16 Dec 2022.
- 31 Mar 2021 Planned primary completion date changed from 26 Feb 2021 to 16 Sep 2022.